← Back to search

GC Therapeutics

GCTx is flipping the entire iPSC differentiation paradigm on its head. Rather than manually iterating through a limited ...

a16zActive

What they do

Problem

Developing reliable iPSC differentiation protocols is slow, manual, and limited by existing biological hypotheses.

Solution

A Human TFome platform that uses large-scale combinatorial transcription factor screening to discover novel iPSC differentiation protocols and cell fates.

Who it's for

Biomedical researchers and biopharma/cell therapy teams developing iPSC-derived cell types.

Company timeline

Similar startups

Culture Biosciences
We grow cells for biotech companies.
Benchling
Unlocking the power of biotech with modern software for modern science
ResistanceBio
We solve drug resistance for cancer
Nomic Bio
Nomic is doing for proteins what Illumina has done for DNA
Formation Bio
Pharma represents one of the biggest industries in the world. The top…
Circumvent
Utilizing monogenic disorders to inform and solve highly complex…